Login to Your Account


Unnatural amino acids improve ADC precision

By Anette Breindl
Science Editor

Tuesday, January 21, 2014
When they work, antibody-drug conjugates (ADCs) have it all: The precise targeting capability of an antibody allows clinicians to treat patients with drugs that are too toxic to be delivered systemically. The approach has seen successes as well as failures. The first approved ADC, Mylotarg, (gemtuzumab ozogamicin for injection, Pfizer Inc.) was ultimately withdrawn from the market because of issues with the linker technology. Last year’s Phase III failure of Pfizer’s inotuzumab ozogamicin was another reminder that there’s no guarantee of success. (See BioWorld Today, Oct. 15, 2010, and May 22, 2013.)

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription